People with type 2 diabetes treated with metformin plus a sulfonylurea with high affinity for cardiac mitochondrial adenosine triphosphate–sensitive potassium (mitoK ATP) channels, such as glyburide ...

Background and Goal: Sulfonylureas are a class of oral medications used to manage blood glucose levels in patients with type 2 diabetes. These drugs increase insulin production regardless of blood ...

Please provide your email address to receive an email when new articles are posted on . “The current study provides important information for the practicing clinician,” Christianne L. Roumie, MD, MPH, ...

Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...

A European consensus statement advises limiting routine use of sulfonylureas for the treatment of type 2 diabetes to "settings that are resource-constrained and in the short term." The authors point ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “Patients using insulin or sulfonylurea are at a high ...

Background and goal: Sulfonylureas are a class of oral medications used to manage blood glucose levels in patients with type 2 diabetes. These drugs increase insulin production regardless of blood ...

Neonatal diabetes can result from mutations in either Kir6.2 or SUR1 subunits of the pancreatic potassium ATP channel, which disrupt insulin release. Sulfonylureas close these channels and restore ...

A comparative effectiveness research study compared MACE rates among initiators of sulfonylureas versus DPP4 inhibitors for T2D. Glipizide in particular showed a significant link to cardiovascular ...

The prevalence of impaired awareness of hypoglycemia (IAH) is high among patients using sulfonylureas long term, according to a study published in the July/August issue of the Annals of Family ...